Other Barks & Bites for Friday, March 27: Trademarks Evoking Fictitious Heritage May Be Deceptive Under EU Law; March Madness TRO Nixed by District Judge; EU Patent Applications Surpass 200K for First Time in 2025

This week in Other Barks & Bites: Merck enters into a $6.7 billion agreement to purchase Terns Pharma to improve its pipeline of experimental cancer therapies; the Federal Circuit says that common law principles prevented Ascendis Pharma from obtaining a mandatory stay in a second lawsuit including the same claims as a first complaint that was voluntarily dismissed; and more.

CAFC Affirms District Court’s Denial of Mandatory Stay for ITC Respondent Who Voluntarily Dismissed Complaint

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc., affirming a district court order that upheld the U.S. District Court for the Northern District of California decision denying Ascendis’s motion for a mandatory stay under 28 U.S.C. § 1659(a)(2). The ruling concluded that Ascendis was not entitled to a mandatory stay because Ascendis voluntarily dismissed its original complaint and filed a virtually identical refiled complaint to restart the statutory deadline. Judge Stoll authored the opinion, joined by Judges Lourie and Chen.

U.S. Government Says SCOTUS Should Skip Pharma Companies’ Challenge to Medicare Negotiation Program

The U.S. government filed its brief in opposition yesterday to Janssen Pharmaceuticals and Bristol Myers Squibb Company’s (BMS) petition for writ of certiorari challenging the government’s Medicare Drug Price Negotiation Program. A split U.S. Court of Appeals for the Third Circuit decision  in September 2025 affirmed a grant of summary judgment to the government that the imposition of the Program via the Inflation Reduction Act (IRA) does not violate the companies’ constitutional rights.

IPWatchdog LIVE 2026: What Big Tech Actually Wants from Your Patent, and What Sends It Straight to the Back Burner

A panel on day three of IPWatchdog LIVE 2026 offered the IP community a candid look at how large operating companies actually evaluate and respond to patent assertions. The answers carry direct implications for every practitioner advising clients on the sell side of a transaction. The session, titled The Big Tech View on Patents and the Patent Market, featured Russell Binns (Allied Security Trust (AST)), Ola Adekunle (Google), Caroline Pinkston (Hewlett Packard Enterprise (HPE)), and Dean Geibel (Samtec).

Contentious House USPTO Oversight Hearing Centers on PTAB Reforms, Trump’s Political Influence

Today, the U.S. House of Representatives Judiciary Committee’s Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet conducted its first oversight hearing of the U.S. Patent and Trademark Office (USPTO) during the second Trump Administration. The harshest lines of questioning for USPTO Director John Squires during the hearing were reserved for the agency’s notice of proposed rulemaking (NPRM) to reform rules of practice at the Patent Trial and Appeal Board (PTAB) as well as President Trump’s political influence at the agency. During the hearing, Squires also confirmed that the agency’s Patent Public Advisory Committee (PPAC) would soon be revived, following an offer to join PPAC extended last night to an undisclosed independent inventor.

Supreme Court Reverses $1 Billion Verdict, Rules Cox Not Contributorily Liable for Subscribers’ Copyright Infringement

The U.S. Supreme Court on Wednesday reversed a decision by the U.S. Court of Appeals for the Fourth Circuit, ruling that internet service provider Cox Communications, Inc., is not contributorily liable for its subscribers’ copyright infringement. In a 7-2 decision authored by Justice Thomas, the Court held that a service provider is contributorily liable for a user’s infringement only when it intended for its service to be used in that way, which is established only if the provider either encouraged the infringement or designed the service specifically to facilitate it.

Mercola is Seeking a Patent Paralegal

Mercola is managing a high-volume patent pipeline (~200 applications) across multiple advanced technology domains and is seeking experienced contract Patent Paralegals to support prosecution at scale. This is not a typical low-volume IP role. You will work directly with the inventor and patent counsel to ensure accuracy, consistency, and flawless USPTO filing execution across a complex and fast-moving portfolio spanning biotech, AI/software, medical devices, and consumer health innovations. This is a full-time, temporary, fully remote position (USA).

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates